Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Medazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 8/20 | 0.97 |
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.97 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.60 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.60 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.60 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.60 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.60 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.60 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.60 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.60 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.60 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.60 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.60 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.60 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.60 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medazepam SCHEMBL18472 | 0.99 | OPRK1 (1.00) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| Medazepam SCHEMBL11658148 | 0.99 | OPRK1 (1.00) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| Medazepam SCHEMBL29642025 | 0.99 | OPRK1 (1.00) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL14018729 | 0.90 | OPRK1 (0.84) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| Medazepam SCHEMBL30366342 | 0.85 | OPRK1 (0.76) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL9472878 | 0.85 | OPRK1 (0.76) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL11680057 | 0.85 | OPRK1 (0.76) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL9472170 | 0.85 | OPRK1 (0.75) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| Hydrochloric Acid SCHEMBL11855025 | 0.84 | OPRK1 (0.70) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL3235774 | 0.83 | OPRK1 (0.73) | OPRK1PDE4DNR1I2ADORA3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2011081608-A1 | VOICE ENTRY SYSTEM FOR MOBILE PHONES AND EMAIL | DALI MOHAMAD HASSAN (SY) | 2011-07-07 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260023375-A1 | METHODS AND SYSTEMS FOR DECENTRALIZED STEADY STATE ERROR CANCELLATION IN LARGE SCALE, INTERCONNECTED SYSTEMS | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2026-01-22 | — | — | US | disclosed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250387462-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | AKAGERA MEDICINES, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-4049666-A | THE 2-(N-(HALOALKYL OR HALOACYL)-N-(ACYLOXYALKYL OR CARBOBENZOXYALKYL)AMINOPHENYL) PYRIDYL KETONE INTERMEDIATES | HOFFMAN-LA ROCHE INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-4049667-A | THE 2-(N-(HALO-CARBALKOXY-ALKYL OR ACYL)-N-(ACYLOXYALKYL OR CARBOBENZOXYALKYL)AMINOPHENYL) PYRIDYL KETONE INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-4017532-A | SEDATIVES, MUSCLE RELAXANTS, ANTICONVULSANTS | HOFFMANN-LA ROCHE INC. (US) | 1977-04-12 | — | — | US | disclosed |
| US-4017531-A | SEDATIVE, MUSCLE RELAXANT, ANTICONVULSANT | HOFFMANN-LA ROCHE INC. (US) | 1977-04-12 | — | — | US | disclosed |
| US-4014916-A | SEDATIVES, MUSCLE RELAXANTS AND ANTICONVULSANT AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-03-29 | — | — | US | disclosed |
| US-3997591-A | SEDATIVES, MUSCLE RELAXANT, ANTICONVULSANT | HOFFMANN-LA ROCHE INC. (US) | 1976-12-14 | — | — | US | disclosed |
| US-3965151-A | 2-(AMINO OR AMIDO)-BENZOPHENONES | HOFFMANN-LA ROCHE INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387462-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | CD4, MICA, LNPK | OPRK1 3932/4885PDE4D 4183/4885HTR2C 4840/4885 |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | OPRK1 377/4885PDE4D 3138/4885HTR2C 816/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | OPRK1 431/4885PDE4D 2003/4885HTR2C 208/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | OPRK1 2725/4885PDE4D 1590/4885HTR2C 1730/4885 |
| US-20260023375-A1 | METHODS AND SYSTEMS FOR DECENTRALIZED STEADY STATE ERROR CANCELLATION IN LARGE SCALE, INTERCONNECTED SYSTEMS | TMCO1, IPMK, NCS1 | OPRK1 4682/4885PDE4D 1078/4885HTR2C 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.